Explore our exciting drug candidates and the indications we are targeting
Overview of Sathgen's innovative pipeline of oncology therapies
With over 20 compounds in our oncology pipeline, we are committed to developing novel therapies to combat cancer. Our first target is Triple Negative Breast Cancer, a highly metastatic disease with a high mortality rate affecting 340,000 patients worldwide. Limited treatment options result in low patient survival, with 200,000 deaths around the world in 2020 alone. MSP008-22, our first-in-class therapy with a novel mechanism-of-action, has demonstrated efficacy in cancer models, with an excellent safety profile. With patent approval in numerous countries, we are confident that MSP008-22 will make a significant impact in the fight against Triple Negative Breast Cancer as well as other types of cancer.
Brief description of each drug class and its potential indications
We currently have 5 (out of 50) MSP-derived molecules in the pipeline. Of these, MSP008-22 has been developed the furthest with ongoing first-in-human trials. MSP008-22 has also shown an excellent efficacy and safety profile in pre-clinical models. MSP molecules have shown anti-cancer activity against Triple Negative Breast Cancer, Prostate Cancer, Oral Cancer, Glioblastoma, Hepatic Cancer, Cervical Cancer, Colon Cancer, and Lung Cancer. Currently, MSP008-22 has ongoing phase I clinical trials in patients with advanced solid tumors as well as in healthy individuals to test for the pharmacokinetics and safety of the drug. Additionally, MSP008-22 has also shown anti-viral activity against SARS-CoV-2 in preclinical models, indicating its potential as an anti-viral drug.
It is similar to the MSP group in its properties. Of the 116 tested, 6 were selected due to their safety and efficacy profile. SBGBL has shown anti-cancer activity against Triple Negative Breast Cancer, Prostate Cancer, Oral Cancer, Glioblastoma, Hepatic Cancer, Cervical Cancer, Colon Cancer, and Lung Cancer.
It is a structure activity relationship (SAR) positive molecule that blocks stem cell activity in cancer cells by targeting pathways essential for cancer cell survival. We have currently filtered down to 12 LSP-derived molecules that show no toxicity and high anti-cancer activity against Triple Negative Breast Cancer, Prostate Cancer, Oral Cancer, Glioblastoma, Hepatic Cancer, Cervical Cancer, Colon Cancer, and Lung Cancer.
It is an SAR active potential best-in-class molecule that was developed based on two tyrosine kinase inhibitors. We have currently developed 26 MET-derived molecules that are still being tested for their toxicity and anti-cancer potential.